Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Neuro-Oncology
•
Pediatric Hematology/Oncology
•
Neurology
•
Child Neurology
•
Neurogenetics
At what point should surgical intervention be considered for vestibular schwannomas or other tumors in pediatric NF2 patients?
Related Questions
What workup do you consider for a developmentally typical child with multiple large café au lait macules but no other signs of neurofibromatosis?
Would you recommend a specific workup or change in management for patients with severe, persistent deficits from methotrexate leukoencephalopathy?
What approach do you use when treating adult diffuse gliomas with H3-G34 mutations, now classified into their own category under the 2021 glioma guidelines?
In pediatric patients with low-grade gliomas showing prolonged response or stable disease on tovorafenib, how would you adjust the duration of therapy?
Would you consider combining tovorafenib and trametinib as dual therapy?
What was the rationale behind using RANO-HGG criteria instead of RAPNO criteria for the primary endpoint in the FIREFLY-1 trial for pLGG?
How do you approach treatment of sub-total resected ZFTA fusion ependymoma after radiation therapy in a young adult?
Would you recommend anticoagulation in a pediatric patient with metastases in a dural venous sinus?
Is there utility to ordering biochemical screening labs for global developmental delay?
How do you use aspirin in pre-symptomatic Sturge Weber patients?
